Skip to content

US · NKTR · BIOTECHNOLOGY

Nektar Therapeutics (NKTR) intrinsic value and stock valuation

$30.20as of 2026-11-21 · Mkt cap 2.1B

Data updated · price as of 2026-11-21

Strongly overvaluedIC value is more than 50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Nektar Therapeutics DCF and intrinsic value

InvestorsCraft values NKTR with the Chepakovich two-stage DCF model — currently rated strongly overvalued. How the model works · Run your own DCF prefilled from NKTR’s statements →

Nektar Therapeutics Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Francisco, CA 94158 nektar.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$55.2M-18.4% 5y CAGRd
20112025
Net income
-$-164.08M
20112025
Free cash flow
-$-208.68M
20112025
Total equity
$89.8M-39.2% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$55.2M$98.4M$90.1M$92.1M$101.9M
Operating income-$-130.77M-$-105.2M-$-137.43M-$-240.24M-$-446.1M
Net income-$-164.08M-$-118.96M-$-276.06M-$-368.2M-$-523.84M
EPSd-$-9.73M-$-8.68M-$-21.79M-$-29.5M-$-42.87M
Operating cash flow-$-208.51M-$-175.71M-$-192.61M-$-304.01M-$-412.66M
Capital expenditure-$-170K-$-1.47M-$-860K-$-5.68M-$-14.99M
Free cash flow-$-208.68M-$-177.18M-$-193.47M-$-309.68M-$-427.65M
Total assets$280.4M$303.9M$398M$710.6M$1.12B
Total debt$148.9M$102.6M$117.8M$131.5M$143.2M
Net debt$133.8M$58.3M$82.5M$43.3M$118M
Total equity$89.8M$60.7M$131M$366.6M$679.5M
Cash and short-term investments$245.8M$255.2M$303.6M$505M$734M
Income statement
20252024202320222021
Revenue$55.2M$98.4M$90.1M$92.1M$101.9M
Cost of revenue$0.00$30.7M$36.6M$21.6M$24.9M
Gross profit$55.2M$67.7M$53.5M$70.4M$77M
Research and development expenses$117.3M$120.9M$114.2M$218.3M$400.3M
Selling, general and administrative expenses$68.7M$76.8M$77.4M$92.3M$122.8M
Other expenses$0.00-$-24.72M-$-680K$0.00$0.00
Operating expenses$186M$172.9M$190.9M$310.7M$523.1M
Cost and expenses$186M$203.6M$227.6M$332.3M$548M
Interest income$10.4M$14.5M$19M$6.78M$2.73M
Interest expense$26.2M$28.1M$25.3M$28.9M$47.3M
Depreciation and amortization$1.03M$4.39M$7.82M$12.2M$14.2M
Ebitda-$-137M-$-86.7M-$-243.11M-$-323.87M-$-461.82M
Operating income-$-130.77M-$-105.2M-$-137.43M-$-240.24M-$-446.1M
Total other income/expenses, net-$-33.44M-$-14M-$-138.83M-$-124.75M-$-77.18M
Income before tax-$-164.21M-$-119.2M-$-276.26M-$-364.98M-$-523.28M
Income tax expense-$-140K-$-240K-$-200K$3.21M$560K
Net income-$-164.08M-$-118.96M-$-276.06M-$-368.2M-$-523.84M
Weighted average shares outstanding$16.9M$13.7M$12.7M$12.5M$12.2M
Weighted average diluted shares outstanding$16.9M$13.7M$12.7M$12.5M$12.2M
Balance sheet
20252024202320222021
Cash and short-term investments$245.8M$255.2M$303.6M$505M$734M
Net receivables$1.78M$1.61M$2.25M$8.4M$22.5M
Inventory$0.00$0.00$16.1M$19.2M$15.8M
Total current assets$266.3M$261.3M$330.7M$546M$795.6M
Property, plant and equipment, net$5M$11.8M$36.9M$85.9M$177.5M
Goodwill and intangible assets$0.00$0.00$0.00$76.5M$76.5M
Long-term investments$3.49M$26.1M$25.8M$0.00$64.8M
Total non-current assets$14.1M$42.6M$67.3M$164.6M$321.6M
Total assets$280.4M$303.9M$398M$710.6M$1.12B
Accounts payable$10.8M$11.6M$9.85M$13M$9.75M
Short-term debt$20.5M$19.9M$19.3M$18.7M$17.4M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$53.5M$61.4M$51.3M$68.2M$85.2M
Long-term debt$128.4M$82.7M$98.5M$112.8M$125.7M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$137M$181.7M$215.8M$275.8M$352.5M
Capital lease obligations$65.3M$102.6M$117.8M$131.5M$143.2M
Total liabilities$190.6M$243.1M$267.1M$344M$437.7M
Common stock$0.00$20K$20K$20K$20K
Retained earnings-$-3.76B-$-3.6B-$-3.48B-$-3.2B-$-2.83B
Accumulated other comprehensive income (loss)$20K$60K$80K-$-6.91M-$-4.16M
Total equity$89.8M$60.7M$131M$366.6M$679.5M
Total investments$234.1M$237.1M$294.2M$416.8M$773.6M
Total debt$148.9M$102.6M$117.8M$131.5M$143.2M
Net debt$133.8M$58.3M$82.5M$43.3M$118M
Cash flow statement
20252024202320222021
Net income-$-164.08M-$-118.96M-$-276.06M-$-368.2M-$-523.84M
Depreciation and amortization-$-4.49M$4.39M$7.82M$13M$14.2M
Stock-based compensation$12.7M$21.6M$33.4M$57.3M$94.7M
Change in working capital-$-37.02M-$-6.24M-$-19.8M$490K-$-23.08M
Accounts receivable$0.00-$-3.04M$4.78M$16.5M$12.4M
Inventory$0.00$500K$700K-$-3.4M-$-510K
Accounts payable-$-620K$2.67M-$-2.88M$3.1M-$-11.69M
Net cash provided by operating activities-$-208.51M-$-175.71M-$-192.61M-$-304.01M-$-412.66M
Investments in property, plant and equipment-$-170K-$-1.47M-$-860K-$-5.68M-$-14.99M
Acquisitions, net-$-700K$65.4M$0.00$13.2M-$-217.77M
Net cash used for investing activities-$-1.2M$142.6M$139.6M$365.8M$202.8M
Common stock issued$180.6M$30.1M$30K$760K$33.2M
Common stock repurchased$0.00-$-3M$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$180.6M$42.1M$30K$1.51M$36.2M
Net change in cash-$-29.14M$8.97M-$-52.95M$63M-$-173.74M
Cash at end of period$15.1M$44.3M$35.3M$88.2M$25.2M
Operating cash flow-$-208.51M-$-175.71M-$-192.61M-$-304.01M-$-412.66M
Capital expenditure-$-170K-$-1.47M-$-860K-$-5.68M-$-14.99M
Free cash flow-$-208.68M-$-177.18M-$-193.47M-$-309.68M-$-427.65M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Nektar Therapeutics

        Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.

        CEO
        Howard W. Robin
        Employees
        63
        Beta
        1.14

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Nektar Therapeutics (NKTR)?

        Nektar Therapeutics (NKTR) is currently strongly overvalued based on the InvestorsCraft IC model — IC value is more than 50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is NKTR undervalued?

        NKTR trades at a price of $30.20 (Nov 21, 2026): strongly overvalued — IC value is more than 50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.